RxDoctor Payments Data

Jeffrey Liu, MD

Ophthalmology · Mountain View, CANPI 1013145127

Payments from drug & device makers

$44,166in general payments, 2019–2025

Across 296 payments — averaging $149.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$40K
  • Biotissue Holdings Inc.$812
  • Eyevance Pharmaceuticals LLC$671
  • Tarsus Pharmaceuticals, Inc.$428
  • Aerie Pharmaceuticals, Inc.$311
  • Sun Pharmaceutical Industries Inc.$297
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$281%
  • Food & beverage$4,13999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,166 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$463,919
Medicare patients
894
Services billed
3,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine13$23,827
XdemvyLotilaner12$22,042
Prednisolone Acetate190$6,809
LumiganBimatoprost16$6,741
Latanoprost218$3,195
Fluorometholone46$2,994
TafluprostTafluprost/Pf15$2,806
ValacyclovirValacyclovir Hcl25$2,696
Tobramycin-DexamethasoneTobramycin/Dexamethasone65$2,640
Travoprost15$2,092
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,087
Loteprednol Etabonate18$2,026
Timolol Maleate65$1,839
Brimonidine Tartrate33$1,608
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$237$30,56829 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$428$22,04212 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$76$2,02618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →